Nasal universal vaccine shields mice from viruses, bacteria, and allergies
A nasal spray vaccine, GLA-3M-052-LS+OVA, protected mice against SARS-CoV-2 and other coronaviruses, guarded against certain bacteria, and reduced allergy-related lung symptoms, by engaging both innate and adaptive immunity; with three doses, it lowered lung viral loads and sped up immune responses, and human trials could begin with a target availability in 5–7 years if results translate to people.
